Polio future or investigational therapies: Difference between revisions
Joao Silva (talk | contribs) No edit summary |
m Bot: Removing from Primary care |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Although at the present moment there are no [[antiviral]] treatments for [[poliovirus]], [[vaccination]] has shown to be an effective approach towards the eradication of the [[poliovirus|virus]]. Future studies are required in order to evaluate the best approach for [[immunization]] of the remaining [[endemic]] areas. Following the eradication of [[serotype]] 2, replacement of trivalent OPV for bivalent OPV has been discussed, thereby eliminating the risk of reinsurance of [[vaccine]] virus [[serotype]] 2.<ref name="pmid21675884">{{cite journal| author=Aylward B, Yamada T| title=The polio endgame. | journal=N Engl J Med | year= 2011 | volume= 364 | issue= 24 | pages= 2273-5 | pmid=21675884 | doi=10.1056/NEJMp1104329 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21675884 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | |||
Latest revision as of 23:46, 29 July 2020
|
Polio Microchapters |
|
Causes |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polio future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Polio future or investigational therapies |
|
Risk calculators and risk factors for Polio future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Although at the present moment there are no antiviral treatments for poliovirus, vaccination has shown to be an effective approach towards the eradication of the virus. Future studies are required in order to evaluate the best approach for immunization of the remaining endemic areas. Following the eradication of serotype 2, replacement of trivalent OPV for bivalent OPV has been discussed, thereby eliminating the risk of reinsurance of vaccine virus serotype 2.[1]
References
- ↑ Aylward B, Yamada T (2011). "The polio endgame". N Engl J Med. 364 (24): 2273–5. doi:10.1056/NEJMp1104329. PMID 21675884.